Hepatocellular carcinoma (HCC) is a highly metastatic cancer with very poor prognosis. AMP activated kinase (AMPK) constitutes a candidate to inhibit HCC progression. First, AMPK is downregulated in HCC. Second, glucose starvation induces apoptosis in HCC cells via AMPK. Correspondingly, metformin activates AMPK and inhibits HCC cell proliferation. Nevertheless, the effect of AMPK activation on HCC cell invasiveness remains elusive. Here, migration/invasion was studied in HCC cells exposed to metformin and glucose starvation. Cell viability, proliferation and differentiation, as well as AMPK and PKA activation were analyzed. In addition, invasiveness in mutants of the AMPKα activation loop was assessed. Metformin decreased cell migration, invasion and epithelial-mesenchymal transition, and interference with AMPKα expression avoided metformin actions. Those antitumor effects were potentiated by glucose deprivation. Metformin activated AMPK at the same time that inhibited PKA, and both effects were enhanced by glucose starvation. Given that AMPKα(S173) phosphorylation by PKA decreases AMPK activation, we hypothesized that the reduction of PKA inhibitory effect by metformin could explain the increased antitumor effects observed. Supporting this, in AMPK activating conditions, cell migration/invasion was further impaired in AMPKα(S173C) mutant cells. Metformin emerges as a strong inhibitor of migration/invasion in HCC cells, and glucose restriction potentiates this effect.
Hepatocellular carcinoma (HCC) is a rather frequent and much more aggressive cancer, mainly due to its feature of developing intra and extrahepatic metastasis at an extremely rapid rate1. Accumulation of genetic and microenviromental changes take place in hepatocytes during chronic inflammation associated to a basal liver disease in 90% of HCC patients, and this scenario promotes malignant transformation from early dysplastic to multiple and genetically-heterogeneous nodules2. Despite administration of surgical or current pharmacological treatment, most people diagnosed with HCC die within two years of being diagnosed, and this statistics positions HCC as the second cause of cancer death worldwide2,3. Elucidation of the mechanisms controlling cell proliferation and, specially, migration constitutes a main issue for understanding the bases of the disease and hence for foreseeing therapeutic strategies to limit its development.
In the last years, AMP activated kinase (AMPK) signaling was demonstrated to be involved in HCC etiology and has become a promising therapeutic target4,5,6,7. In fact, AMPK activity is significantly decreased in tumor compared with non-tumor region, and this downregulation is associated with worst HCC prognoses4,6. AMPK consists of a heterotrimer of catalytic (α), regulatory (β), and activation (γ) subunits, which response to energy stress in most tissues and cell types. Upon activation, AMPK enhances fatty acids and glucose oxidation and inhibits protein biogenesis thus leading to the restitution of ATP levels8. In addition, AMPK signals cell cycle arrest and survival regulation in tumor cells9,10,11. Moreover, even when it has not been as well characterized, AMPK activation can also affect cell motility and hence it can decrease the metastatic capacity of cancer cells12,13,14. We have recently demonstrated that AMPK is the key kinase pathway that controls cell death in HCC cells undergoing glucose restriction: AMPKα silencing in HCC cells prevents both cell cycle arrest and apoptosis induced by glucose starvation15. However, scanty information exists regarding the involvement of AMPK signaling in HCC cell migration. Besides the allosteric effect of AMP, activation of AMPK during nutritional stress requires phosphorylation of Thr172 residue of AMPKα by LKB18. AMPK activation can be negatively regulated by phosphorylation of different regulatory residues by PKA and/or AKT16,17,18. Our previous findings indicated that Ser173 phosphorylation by PKA reduces phospho-AMPKα(T172) levels and prevents apoptotic activation in HCC cells subjected to nutritional stress15.
Metformin, an antidiabetogenic drug which in recent years has entered into the limelight of promising anticancer drugs19, is a bonafide AMPK activator. Metformin activates AMPK via affecting mitochondrial respiration complex I and AMP/ATP ratio20, as well as by favoring LKB1 activation21,22. Furthermore, it has been shown that metformin can also indirectly activate AMPK by inhibiting PKA and therefore decreasing AMPKα(S173) phosphorylation23. Recent studies showed that metformin diminishes proliferation in HCC cells in vitro or in xenotransplanted nude mice4. Because of its antiproliferative effects, metformin is nowadays being studied for cancer therapy in diverse clinical trials. Nevertheless, AMPK participation in the regulation of HCC cell migration and metformin putative actions on this pathway remain elusive.
We hypothesize that AMPK signaling can inhibit HCC cell migration and that the extent of this effect depends on AMPK activation effectiveness in each cellular context. In this study, we aimed to analyze migratory capacity in HCC derived cells treated with metformin and combined with glucose starvation condition. We presented strong evidence supporting that metformin exerted a considerable antimigratory effect in HCC cells which was potentiated by glucose restriction. Results on the migratory response of HCC cells with non phosphorylatable mutation of S173 residue of AMPKα were also analyzed.
Metformin decreases migration in two HCC cell lines with different migratory behavior
HepG2/C3A and HuH-7 cell number after 24 h metformin incubation at a rank of concentrations most frequently used for cancer cell treatment was screened by MTT assay (Fig. 1a). Remarkably, 1 and 5 mM metformin led to mild (15–30%) decreases in total viable cells. The higher concentrations of 10 and 20 mM led to decreases in cell number which surpassed 50%. Proliferation rates in both cell lines subjected to metformin treatment at the lower concentrations were evaluated by BrdU incorporation assay: After 24 h treatment neither 1 mM nor 5 mM metformin induced any significant change in BrdU incorporation. On the other hand, after 48 h treatment, 1 mM metformin showed only a tendency to elicit an antiproliferative effect, although 5 mM metformin significantly decreased the number of positive nuclei (Fig. 1b).
In turn, the effect of metformin at these lower concentrations on 2D cell migration was evaluated by wound healing assays. The effects of two different AMPK activating conditions, AICAR and glucose deprivation, were also analyzed and compared using the same assay (Fig. 1d). Metformin significantly inhibited cell migration in a dose dependent manner in HepG2/C3A and HuH-7 cells (Fig. 1d). This effect was similar in both cell lines, regardless of their different migratory efficiencies, and it was in accordance with the extent in AMPK activation, which was mild with 1 mM metformin (+77%) and greater with 5 mM metformin (+228%) (Fig. 1c). In fact, the distance advanced by the cells 24 h after wounding was reduced by around 30% or 60% of the control group when cells were treated with metformin at 1 or 5 mM, respectively (Fig. 1d). The velocity of migration of individual cells in the wound front was also estimated by time-lapse studies. These results see Supplementary Fig. 1 corroborated that the effect of metformin on the migratory function detected by wound healing assay as a global measure of collective migration was similar to that observed by single-cell tracking.
Taking together, these results suggested that AMPK activation entailed antimigratory effects in HCC cells, and that 1 mM metformin was already effective in inhibiting the cell migratory ability, whilst only subtly induced citotoxicity.
Metformin effects on transwell migration/invasion assay in HCC cells
To further characterize the effects on cell migration/invasion, we performed a 3D cell migration/invasion assay by analyzing the ability of cells to migrate through a matrigel coated membrane. Figure 2a depicts typical captures of matrigel coated transwells after the different treatments. Cell invasiveness decreased, approximately, to 40 and 60% of control levels in C3A and HuH-7 cells, respectively, when treated with 1 mM metformin, and to 20% in the presence of 5 mM metformin (Fig. 2b). Collectively, these results showed that metformin was a potent inhibitor of migration/invasion in HCC derived cells.
Silencing of AMPK suppresses metformin antimigratory and anti-invasive effects
The expression of AMPKα was diminished with specific siRNAs (AMPK KD) in HepG2/C3A and HuH-7 cells (Fig. 2c). Phosphorylation of AMPKα (Thr172) and ACC(Ser78/80) was detected in AMPKα silenced cells with or without 1 mM metformin in order to corroborate the involvement of AMPK signaling. We found that metformin-induced phosphorylations of AMPKα and ACC were abrogated in AMPK KD cells (Fig. 2d).
In addition, given that during energetic stress p53 status in hepatic cells seems to be tightly regulated by AMPK activity24, together with the fact that we previously observed increases of the p53 transactivated proteins p21 and Puma after AMPK activation by glucose starvation in HCC cells15, we decided to evaluate p53 levels in control and AMPK silenced HCC cells treated with metformin. Metformin entailed an augment of total p53 and this putative stabilization was dependent on AMPK. In fact, negligible amounts of p53 were observed in AMPK KD cells (Fig. 2d).
Migration and invasion assays were performed in control and AMPK KD cells in the presence of metformin. The interference of AMPKα expression abrogated the inhibition of migration (Fig. 2e) and invasion (Fig. 2f) elicited by 1 mM metformin in HCC cells. Besides, migration studies carried out in the p53-null cell line Hep3B demonstrated no inhibitory effects of metformin See Supplementary Fig. 2. These results suggested that an intact AMPK-p53 axis was necessary to observe the antimigratory effects of metformin in HCC cells.
Metformin promotes acquisition of differentiated epithelial phenotype
Expression of epithelial and mesenchymal markers was evaluated. E-cadherin levels were significantly increased whilst vimentin levels were significantly decreased after being treated with metformin, at 1 or 5 mM, for 24 h (Fig. 3a). In spite of their tumor origin, HepG2/C3A cells can develop pseudocanaliculi, which resemble the epithelial structures typical of differentiated hepatocytes25. Considering that cell migration depends on changes in polarity associated to loss of epithelial features, cell differentiation was evaluated as the extent of formation of pseudocanaliculi in HepG2/C3A cells. In accordance with its antimigratory effect, 1 mM metformin increased the number of these canalicular structures in HCC cells (Fig. 3b). In association with this increase in differentiation, E-cadherin protein levels in these cells kept significantly augmented after 72 h treatment with 1 mM metformin (Fig. 3b). Altogether, these results indicated that metformin inhibited epithelial-mesenchymal transition (EMT) in HCC cells.
Combination of metformin and glucose deprivation enhanced the inhibition of HCC cell migration and invasion
In a previous work, we demonstrated that AMPK is the central kinase controlling apoptotic activation in HCC cells undergoing glucose starvation. In fact, AMPK activation after glucose deprivation is rapid and marked and its silencing completely blocks the augment in the apoptotic population induced by glucose deprivation15. Nevertheless, there is no data available regarding the putative effect of this activation on cell migration. Metformin is a well-known antiproliferative and cytotoxic drug, either alone or in combination with another antitumor treatment in diverse cells26,27,28. In HCC derived cells metformin (5 to 10 mM) leads to cell cycle arrest4,23,29, and apoptosis30. Therefore, we studied if any additive or synergic effect on cell cycle or death, and, more intriguing, on cell migration could be produce by combination of glucose restriction and metformin treatment in HCC cells.
Our results showed that 1 mM metformin was not enough to produce cell cycle arrest after 48 h of treatment (Fig. 4a). However, the same treatment conditions significantly increased total apoptosis to almost 30% of the whole cell population (Fig. 4b). In addition, and in accordance with the literature, 5 mM metformin did achieve both significant cell cycle arrest (Fig. 4a and Supplementary Fig. 3), and apoptotic activation (Fig. 4b). When C3A cells were incubated with 5 mM metformin in a glucose starving condition, the percentage of apoptotic cells was significantly enhanced from 52 to 72% (Fig. 4b), whereas the percentage of non-apoptotic viable cells decreased to 18%. For this reason, cell cycle distribution was not analyzed in this group of cells. These results showed that there was a dose dependent effect of metformin on apoptotic activation which was much more prominent in conditions of nutritional stress.
Once these effects on cell cycle and apoptosis were characterized, the effect of combination of 1 mM metformin with glucose deprivation on migration and invasion in HCC cells was analyzed. In C3A cells, glucose starvation doubled the inhibition of migration induced by 1 mM metformin in control conditions: from −27% to −53% (Fig. 4c). Similar results were obtained for HuH-7 cells see Supplementary Fig. 3. In the same direction, 1 mM metformin combined with glucose deprivation prompted a marked inhibition of invasion in C3A cells when compared to metformin alone: from −48% to −75% (Fig. 4d).
Total viability of glucose starved C3A and HuH-7 cells treated with 5 mM metformin for 24 h decreased to almost 65 and 40% of control levels, respectively see Supplementary Fig. 4. Therefore, the effects of treatment combination on cell migration and invasiveness could not be evaluated for 5 mM metformin, because 24 and 48 h assays were required.
PKA and AMPK signaling in HCC cells exposed to metformin and glucose deprivation
Besides its role as an AMPK activator, there is evidence that metformin also acts as a PKA inhibitor in hepatic cells23. Therefore, we explored if the increase in the antitumor effects of metformin induced by glucose starvation were associated to changes in the activities of these signaling kinases. As a first approach, we analyzed AMPK and PKA activation, by detecting P-AMPKα(T172) and phosphorylation of PKA substrates in HCC cells cultured in the presence of 1 and 5 mM metformin (Fig. 5a). Metformin treatment increased AMPK activation in a dose dependent manner, and decreased PKA activation at 5 mM. When combined treatment of glucose restriction plus 5 mM metformin was analyzed, we observed that PKA activity was almost undetectable, and activation of AMPK was significantly enhanced (Fig. 5b). This hyper-activation of AMPK paralleled the increase in apoptosis observed by Annexin V/IP assays in the 5 mM metformin plus glucose starvation setting.
It is noteworthy that 1 mM metformin plus glucose starvation did not increase P-AMPKα(T172) levels above those levels elicited by single treatments see Supplementary Fig. 5. In this regard, cell cycle and cell death analysis also showed that combination of 1 mM metformin with glucose withdrawal have no additive effects, what, collectively, indicated that apoptotic death levels correlated with the extent of AMPK activation. However, the same combination of treatments did intensify the inhibition of HCC cell migration/invasion, what could be probably due to additional effects of glucose restriction on these functions which were, at least in part, independent of further AMPK activation.
Subsequently, we focused on the negative regulation of AMPK by PKA in HCC cells. We have previously described that cell death induced by glucose withdrawal in HCC cells is conditioned by PKA inhibition of AMPK15 A set of experiments was performed to evaluate migration in the presence of the specifically designed peptide inhibitor of PKA (PKI) (Fig. 5c), 1 mM metformin, or both. Results showed that PKA participated in regulating migration in HCC cells and demonstrated additive effects of PKA inhibition and 1 mM metformin in reducing HCC cell migration (Fig. 5d). Similar data were obtained by using H89 plus 1 mM metformin (data nor shown). We pondered if this axis also affected glucose starvation effects on cell migration. Therefore, we evaluated the effect of the PKA inhibitor H89 on the migratory capacity of control and glucose starved cells. In line with our previous results, inhibition of PKA by H89 reinforced the reduction in the efficiency of C3A cell migration observed during glucose starvation see Supplementary Fig. 6b, and this was associated to the fact that H89 increased AMPK activation in glucose-fasted cells see Supplementary Fig. 6a. Similar results were obtained for HuH-7 cells (data not shown).
All together, these findings supported the hypothesis that PKA counteracted AMPK activation and that higher levels of AMPK activation were achieved in HCC cells when PKA was inhibited by metformin (Fig. 5e).
Contribution of AMPKα Ser173 site to cell migration
We demonstrated that the simultaneous treatment of HCC cells with 5 mM metformin and glucose restriction increased AMPK activation, which was concomitant with a decrease of PKA activation. In this connection, a study focused on the response to glucagon in liver cells, showed that metformin inhibits PKA and, concurrently, the specific phosphorylation of AMPKα(S173) by PKA23. Our own previous results in HCC cells pointed that mutation of AMPKα(S173) to the non phosphorylatable form AMPKα(S173C) enhanced AMPK activation after glucose deprivation and significantly increased apoptotic death15. In the present work, we corroborated that AMPK activation occurred in WT and S173C mutant cells treated with 1 or 5 mM metformin. However, when subjected to 1 mM metformin the mutant clone showed greater induction of T172 phosphorylation. Concomitantly, both in basal and 1mM-metformin conditions, the levels of the epithelial marker E-cadherin were higher in the S173C mutant (Fig. 6a). This indicated that the lack of phosphorylation of S173 (by PKA) favored AMPK activation and hence increased epithelial differentiation. Taking together these results, we hypothesized that the phosphorylation state of this site could modulate AMPK signaling in HCC cells migratory function. To address this hypothesis, wound healing and transwell migration assays were performed in HCC cells harboring non phosphorylatable mutation of the S173 phosphorylation site. In every AMPK activating conditions assessed, migration of AMPKα(S173C) cells was significantly decreased when compared to AMPKαWT cells (Fig. 6b). Besides, when cells were incubated with the concentration of metformin that inhibited PKA (5 mM) the mutation became ineffective (Fig. 6b), which was in accordance with the similar levels of E-cadherin (and activated AMPK) reached in mutant and wild type cells treated with this concentration of metformin (Fig. 6a).
Comparable results were obtained in invasion assays, where, after glucose withdrawal, or incubation with metformin or AICAR, cell invasiveness was significantly decreased in AMPKα(S173C) compared to AMPKαWT cells. As a sake of example, inhibition of invasion increased from 48 to 83% in WT and mutant cells incubated with 1 mM metformin, respectively (Fig. 6c). Summarizing, these results demonstrated that cells harboring an AMPK mutant form that is not inhibitable by PKA had diminished migration and invasion abilities.
EMT is a continuous matter of study in liver cancer due to the presence of fibrosis in the underlying liver disease which, coupled with other special features of the hepatocytes, point to EMT regulation as a target for the control of HCC development31. It is well known that AMPK signals epithelial differentiation in primary cultured hepatocytes. Moreover, activation of AMPK by metformin significantly increases epithelial cell polarity in normal hepatocytes32. However, the putative AMPK role in the regulation of cell migration process during HCC progression remains unexplored. Here, we aimed to study the effect of AMPK activation on migration and invasion in HCC derived cells and, specifically, when they were treated with the emergent anticarcinogen metformin.
Metformin biological mechanisms and their impacts seem very diverse, and further basic and clinical studies are necessary to understand the complete picture of its antitumor actions32,33. In diabetes treatment, metformin has many benefits and a safety dosage, and it became the most useful oral hypoglycemiant34. Interestingly, valuable metformin results in patients supporting its possible role as anticarcinogen come from the reduction of cancer frequencies in diabetic patients35. Moreover, HCC is prevented in metformin treated patients36,37, which is more significant considering that diabetes is a risk factor for HCC2. Metformin concentrates in the liver due to the enrichment of the transport protein OCT1 in hepatic cells, which also transports cations as sorafenib38. Taken together, this background makes HCC a unique candidate for metformin studies.
First, we showed that a concentration of metformin that causes still meager or no effect on cell cycle and death, does induce significant inhibition of cell migration and invasion in two HCC derived cell lines with different migratory efficiencies. Additionally, either the AMP analog AICAR or glucose starvation induced similar reduction of migration. In turn, we found that metformin inhibitory effects on migration and invasion were abrogated in AMPKα silenced cells. Thus, these results supported that, by activating AMPK, metformin could be an effective antimigratory agent in HCC cells. In addition, activation of AMPK by metformin increased cell differentiation and increased E-cadherin while decreasing vimentin expression in HCC cells. These findings suggested that metformin induced inhibition of cell migration/invasion in HCC cells was due, at least in part, to EMT reversal. Similar data were found in studies performed in diverse cancer cells, from melanoma to breast cancer, which show that treatment with metformin or its functional analogue berberine result in significant diminution of cell migration and invasion via AMPK activation and EMT reduction39,40,41,42.
Second, we demonstrated that combination of metformin with glucose starvation leads to an enhanced inhibition of cell migration and invasion in both HepG2/C3A and HuH-7 cells. In previous studies, we characterized the role of AMPK signaling in the response of hepatic cancer cells to glucose withdrawal and demonstrated the rapid AMPK activation during glucose restriction and the resultant induction of both G0/G1 cell arrest and apoptotic death15. Now we showed that glucose restriction also acts as an antimigratory agent, per se. Furthermore, when cells were exposed to metformin during glucose deprivation, the antitumor effects were increased. The impact of glucose restriction on the migratory ability of HCC cells had not been previously characterized. Metabolic stress during tumor formation activates AMPK, what is proposed to act as an initial prosurvival signal43. Nevertheless, most findings in different tumor cells support antitumor effects of AMPK activation by energy stress (starvation or 2-deoxyglucose treatment), including novel putative targets and inhibition of migration and invasion14,44. Further studies will be necessary to determine if one or more of these specific targets involved in migration/invasion are responsible of metformin triggered AMPK signaling and hence inhibit migration and invasion in HCC cells. However, our results support that, at least in part, an intact AMPK-p53 axis is required to signal these inhibitions. In fact, and in accordance with previous evidence observed in normal liver under energetic stress which suggest p53 stabilization by AMPK phosphorylation24, we demonstrated that AMPK activation through metformin is associated with an increase of p53 in HCC cells, and that cells lack of p53 show no inhibition of migration/invasion by metformin. Similar dependence on p53 was suggested in metformin induced apoptosis in breast cancer cells45. Given that p53 per se can regulate EMT and migration/invasion and that p53 also interplays with other direct targets of AMPK implicated in migration and invasion processes in diverse cancer cells, additional approaches of analysis are required to elucidate the role of AMPK-p53 and the downstream actors involved in the regulation of migration and invasion in HCC cells.
More importantly, here, we demonstrated that AMPK activation either by energy stress or by the pharmacological action of metformin led to the inhibition of migration/invasion of HCC cells, which was related with metformin concentrations and, thus, with the extent of AMPK activation. Moreover, glucose deprivation turned HCC cells migratory and invasive properties extremely sensitive to metformin treatment. In addition, metformin treatment of glucose starved cells also increased apoptotic death, what was even more pronounced at a metformin concentration that inhibited PKA activity. In fact, under glucose deprivation, the drastic inhibition of PKA entailed by 5 mM metformin was associated to a major increase of AMPK activation.
Given that metformin treatment reduces PKA mediated phosphorylation of AMPKα(Ser173) and hence facilitates AMPK activation in hepatic cells23, we explored the possible contribution of S173 residue of AMPKα to the inhibition of migration/invasion elicited by AMPK activation. We found that cells harboring the non-phosphorylatable S173C mutation presented decreased migration and invasion efficiencies when subjected to AMPK activating conditions. However, in the presence of 5 mM metformin, a concentration which inhibited PKA, migration was decreased to a minimum irrespective of the mutation of S173. In this sense, we concluded, as a third main point, that S173 phosphorylation constrains AMPK activation and affects migratory functions in such a way that conditions which prevent its phosphorylation by PKA enhance AMPK antimigratory effects.
Results in cultured tumor cells, subjected to their usual in vitro conditions of extremely high supply of glucose and growth factors, are observed with mM instead of μM metformin concentrations, which are the plasmatic levels in patients46. However, those concentrations were unlikely to be supra pharmacological because metformin concentrates in tissues several folds over blood levels and bioavailability in the liver reaches 8 mM47. Moreover, other antitumor effects via AMPK, analyzed firstly in cultured HCC cells, were also demonstrated in HCC cell-xenotransplantated mice treated with metformin at pharmacological doses4,29, this supporting further translational hypotheses and clinical studies with metformin in HCC patients from in vitro evidence. On the other hand, many results encourage the use of caloric restriction or periodic fasting for cancer treatment and prevention, and diverse clinical trials are now in course48. Changes in signaling kinases are proposed to mediate these dietary antitumor effects, and AMPK is one of the candidates which was studied in rodents but not yet in patients. In fact, caloric restriction decreases tumor development in a breast cancer model in mice and this is associated with AMPK activation in tumor, mammary gland and liver49.
Collectively, we presented evidence regarding novel mechanisms responsible for regulating the migratory and invasive abilities of HCC cells. We focused on conditions that enhance AMPK signaling and result in greater inhibition of cell migration and invasion, as AMPK sensitivity to inhibition by PKA. Due to HCC special features, which comprise accumulation of mutations during chronic inflammation and rapid intrahepatic metastasis, it is a molecular/genetically heterogeneous cancer lacking in effective treatment50,51. In this regard, metabolic or dietary interventions combined with drugs targeted to signaling kinases as metformin, accompanied of early detection can be a promising therapy for limiting the rapid metastatic course of this disease.
The hepatocarcinoma cells C3A (HepG2/C3A, a clonal derivative of HepG2, ATCC, Manassas, VA), HuH-7 (JCRB Cell Bank, Tokyo, Japan), and Hep3B (Hep 3B2.1–7, ATCC) were grown with 4.5 g/L glucose DMEM or, in the case of glucose restriction experiments, with no-glucose DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA), supplemented with 10% FBS and antibiotics. When indicated, 1,1-Dimethylbiguanide Hydrochloride (1–20 mM, Metformin) (Santa Cruz Biotechnology Inc., Santa Cruz, CA), the AMPK activator 5-Aminoimidazole-4-carboxamide ribonucleotide (1 mM, AICAR) (Cell Signaling Technology, Danvers, MA) or the PKA inhibitors N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (5 µM, H89) (Santa Cruz Biotechnology Inc.) or Protein Kinase A inhibitor fragment 14–22, myristoylated (10 µM, PKI) (Sigma Chemical Co., St Louis, MO) were added.
Reduction of AMPKα expression
For reducing AMPKα1 protein expression in HCC cells, 21 nucleotide duplexes targeting two specific AMPKα1 sequences and scrambled control were designed and synthesized by Ambion SilencerTMsiRNA (Thermo Fisher Scientific) and cells were transfected, as we previously described15. The target sequences corresponded to AMPKα1 1842–1864: AACATTTCTGCATATTAGGCTCCTGTCTC and 2659–2681: AAGAGCTGAGTTGCATATACTCCTGTCTC, as we previously used15. Experiments were performed 24–48 h after transfection, and the specific decrease in AMPKα expression for both duplexes was confirmed by immunoblotting. Reductions of 70–80% of protein expression were achieved in both cell lines.
Generation of stable cell lines
pCDNA3 plasmid harboring Myc-AMPKα1(WT) and Myc-AMPKα1(S173C)52,53, kindly given by Dr. Dietbert Neumann (Maastricht University), were used to generate populations of C3A cells stably expressing WT and mutated forms of the AMPKα1 verified by detection of cMyc and AMPKα, as we previously described15. The stable clones obtained were grown in a medium containing 200 μg/ml Geneticin (Invitrogen, Thermo Fisher Scientific), in conditions otherwise similar to that of the parental cells.
Cells were cultured in 96-well microplates and methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma Chemical Co., St Louis, MO) was added at the indicated time, as we previously described15. After 2 h, the metabolite produced from viable cells was dissolved in DMSO and absorbance was detected at 540 nm in a microplate reader (Beckman Coulter LD400). Results were expressed as percentage of absorbance in control cells.
BrdU incorporation assay
Cells were plated onto coverslips, subjected to the indicated treatments and then BrdU (10 mM) was added and cells were incubated for additional 3 h. After fixed in 4% paraformaldehyde and permeabilized with Triton X-100, cells were washed three times with PBS for 5 min and DNA was denaturalized by incubating 10 seconds in 50 mM NaOH. After treatment with a blocking solution, the cells were incubated with anti-BrdU antibody (B8434 Sigma Chemical Co.), washed and incubated with secondary antibody, washed once again and incubated with 4′,6-diamidino-2-phenylindole (DAPI, Molecular Probes) for nuclei staining. The cells were then washed and mounted for observation under a fluorescence microscope (Nikon TE200). Independent areas were captured and BrdU-positive nuclei were counted and expressed as percentage (a total of 500 nuclei on average were counted).
Annexin V/propidium iodide assay
Cells were prepared for Annexin V assay (BD Biosciences, San José, CA), as we previously described15. In brief, after gently homogenization in the culture medium and harvest, 100,000 cells were carefully re-suspended and externalization of phosphatidylserine and cell death was assessed by staining with Annexin V-FITC and PI, respectively, coupled to flow cytometric analysis (Cell Sorter BD FACSAria II, BD Biosciences), following the manufacturers’ instructions.
Cell cycle analysis
Cell distribution in the cell cycle was analyzed by determining the cellular DNA content by flow cytometry, as we previously described15. Briefly, 1 × 106 cells were fixed with cold 70% ethanol, washed with PBS and stained with 50 μg/ml propidium iodide (Sigma Chemical Co.) in a buffer solution (0.1% sodium citrate, 0.02 mg/ml RNAse, and 0.3% NP-40). Results were analyzed using WinMDi and Cylchred softwares.
Immunofluorescence confocal microscopy
Cells were grown on glass coverslips and, at the end of experiments, fixed and treated, as we previously described25,54. Briefly, fixed cells were permeabilized and blocked with 0.3% Triton X-100-1% albumin. Then they were incubated for F-actin staining with Alexa 560-conjugated phalloidin (Molecular Probes, Eugene, OR), washed, incubated for nuclei staining with 4′,6-diamidino-2-phenylindole (DAPI, Molecular Probes), and mounted with ProLong (Molecular Probes). Fluorescence was detected by using confocal microscopy (Nikon C1SiR with inverted microscope Nikon TE200). Serial optical sections in the z-axis were collected, and projections were obtained using ImageJ tools. Canalicular structures were identified and quantified, as we previously described25.
Wound healing assay
Cell monolayers were subjected to wound healing assay to measure collective cell migration, as we previously described55, with slight modifications. In brief, cells seeded at 3 × 106 (C3A) or 1,5 × 106 (HuH-7) in DMEM were cultured in 6-well plates (or 24 well-plates in the case of PKI experiments). After 24 h, cells were wounded by dragging a 200-μl pipette tip through the monolayer, washed and subjected to their respective treatments. Microscopic images (Zeiss Axiovert 25) of wounds in the same field were captured when the wound was made (0 h) and 24 h after wounding. The length (μm) advanced by the cells of the wound front was assessed by using ImageJ software. For time lapse studies, cells were cultured in 35 mm dishes and wounds were dragged with a 20-μl pipette tip. The cells were otherwise treated as described above and sequential pictures from the same field over a plate thermostated at 37 °C were automatically captured every 30 min for the last 3 h within 24 h of treatment. The advancing of a single cell in the wound front was assessed (a line segment from the initial to the final centriole position) by using ImageJ software.
Invasion assay was performed using a transwell chamber (Biofil, Beijing, China) with 8 μm pore size polyester membrane filters. The upper side was pre-coated with 250 μg/ml Matrigel (Corning, Corning, NY). Cells were trypsinized and suspended in DMEM containing 1% FBS. Next, 1 × 105 cells were added to the upper chamber, and the lower chamber was filled with complete DMEM medium containing 10% FBS without any modification throughout the experiment. Cells were subjected to their respective treatments for 48 h. After incubating, cells that had invaded the lower chamber were fixed with methanol, stained with 1% Toluidine Blue in 1% borax for 5 min, and counted using an inverted microscope.
Preparation of cell lysates
Whole cell lysates were prepared, as we previously described15. Briefly, cell monolayers were washed, scrapped and harvested by centrifugation. Pellets were incubated for 30 min in RIPA buffer (1% Triton X-100 (v/v), 1% sodium deoxycholate (w/v), 0.1% SDS (w/v), 20 mM Tris, pH 8, 5 mM EDTA, 200 mM NaCl) supplemented with protease (1 mM PMSF, 10 μg/mL leupeptin (Sigma Chemical Co.)) and phosphatase (10 mM NaF, 2 mM Na3VO4, 100 nM calyculin A (Sigma Chemical Co.)) inhibitors, and then sonicated. Protein concentration was measured according to Lowry et al.56.
Total proteins were separated by electrophoresis on SDS-polyacrylamide gels57, and transferred to polyvinylidene difluoride membranes (Perkin Elmer Life Sciences, Boston, MA, USA). Membranes were blocked with 5% non-fat milk/0.3% Tween/PBS. In the case of phospho-ACC and ACC detections, electrophoreses were performed in 6–10% gels for probing in the same samples those greater proteins (phospho-ACC, ACC) with regular size proteins (AMPKα, p53, etc.), and the upper halves of the gels were transfer for 3 h to nitrocellulose membranes and blocked with 3% albumin 0.3%Tween/TBS. All the membranes were washed and incubated overnight with specific primary antibodies [α tubulin (T-5168 Sigma Chemical Co.); p-ACCa (Ser 78/Ser 80)-R, ACCa (D5), p53(DO-1) (sc-30447-R, sc-137104, sc-126 Santa Cruz Biotechnology); phospho-(Ser/Thr) PKA Substrate, AMPKα, Phospho-AMPKα (Thr172), (9621S, 2532, 2535 Cell Signaling Technology); vimentin (M0725 Dako, Denmark); or E-cadherin (610182 BD Biosciences)]. Membranes were probed with the appropriate secondary antibody. Bands were detected by chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ).
Data were expressed as mean ± SEM. Student t test was used for comparison between groups. P < 0.05 was considered statistically significant.
Uchino, K. et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117, 4475–4483 (2011).
Marquardt, J. U., Andersen, J. B. & Thorgeirsson, S. S. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat. Rev. Cancer 15, 653–667 (2015).
Llovet, J. M., Villanueva, A., Lachenmayer, A. & Finn, R. S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat. Rev. Clin. Oncol. 12, 408–24 (2015).
Cheng, J. et al. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PloS One 9, e93256 (2014).
Yu, R. et al. Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. Cancer Cell Int. 14, 49 (2014).
Lee, C. W. et al. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res. 72, 4394–4404 (2012).
Vara, D. et al. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ. 18, 1099–1111 (2011).
Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell. Biol. 13, 251–262 (2012).
Jones, R. G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283–293 (2005).
Liang, J. & Mills, G. B. AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 73, 2929–2935 (2013).
Hardie, D. G. Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? Clin. Cancer Res. 21, 3836–40 (2015).
Nagalingam, A., Arbiser, J. L., Bonner, M. Y., Saxena, N. K. & Sharma, D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res. 14, R35 (2012).
Chou, C. C. et al. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt–MDM2–Foxo3a signaling axis. Cancer Res. 74, 4783–4795 (2014).
Yan, Y. et al. Augmented AMPK activity inhibits cell migration by phosphorylating the novel substrate Pdlim5. Nature Commun. 6, 6137 (2015).
Ferretti, A. C. et al. AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation. Oncotarget 7, 17815–17828 (2016).
Djouder, N. et al. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J. 29, 469-481 (2010).
Hurley, R. L. et al. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J. Biol. Chem. 281, 36662–36672 (2006).
Mankouri, J. et al. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc. Natl. Acad. Sci. USA 107, 11549–11554 (2010).
Sahra, I. B., Le Marchand-Brustel, Y., Tanti, J. F. & Bost, F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9, 1092–1099 (2010).
Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001).
Xie, Z., Dong, Y., Scholz, R., Neumann, D. & Zou, M. H. Phosphorylation of LKB1 at serine 428 by protein kinase C-ζ is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117, 952–962 (2008).
Xie, Z. et al. Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogénesis. Mol. Cell. Biol. 29, 3582–3596 (2009).
Aw, D. K. L., Sinha, R. A., Xie, S. Y. & Yen, P. M. Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells. Biochem. Biophys. Res. Commun. 447, 569–573 (2014).
Prokesch, A. et al. Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis. FASEB J. 31, 732–742 (2017).
Mattaloni, S. M. et al. AKAP350 Is involved in the development of apical “canalicular” structures in hepatic cells HepG2. J. Cell Physiol. 227, 160–171 (2012).
Ben Sahra, I. B. et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70, 2465–2475 (2010).
Silvestri, A. et al. Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions. PloS one 10, e0136250 (2015).
Wang, L. W. et al. Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 14, 7192–7198 (2008).
Miyoshi, H. et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int. J. Oncol. 45, 322–332 (2014).
Bhat, M. et al. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget 8, 50542–50556 (2017).
Giannelli, G., Koudelkova, P., Dituri, F. & Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J. Hepatol. 65, 798–808 (2016).
Fu, D., Wakabayashi, Y., Ido, Y., Lippincott-Schwartz, J. I. & Arias, M. Regulation of bile canalicular network formation and maintenance by AMP-activated protein kinase and LKB1. J. Cell Sci. 123, 3294–3302 (2010).
Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J. & McGuire, D. K. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312, 2668–75 (2014).
Decensi, A. et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila) 3, 1451–61 (2010).
Hassan, M. M. et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116, 1938–46 (2010).
Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606–15 (2013).
Hyrsova, L., Smutny, T., Trejtnar, F. & Pavek, P. Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation. Drug Metab. Rev. 48, 139–158 (2016).
Cerezo, M. et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol. Cancer Ther. 12, 1605–1615 (2013).
Qu, C. et al. Metformin reverses multidrug resistance and epitelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol. Cell. Biochem. 386, 63–71 (2014).
Kim, H. S. et al. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem. Pharmacol. 83, 385–394 (2012).
Park, J. J. et al. Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin β1 signaling. Biochem. Biophys. Res. Commun. 426, 461–467 (2012).
Jeon, S. M., Chandel, N. S. & Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485, 661–665 (2012).
Schaffe, B. E. et al. Identification of AMPK phosphorylation sites reveals a network of proteins involved in cell invasion and facilitates large-scale substrate prediction. Cell Metab. 22, 907–921 (2015).
Li, P., Zhao, M., Parris, A. B., Feng, X. & Yang, X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochem. Biophys. Res. Commun. 464, 1267–1274 (2015).
Lalau, J. D., Lemaire-Hurtel, A. S. & Lacroix, C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin. Drug Invest. 31, 435–438 (2011).
Martin-Castillo, B., Vazquez-Martin, A., Oliveras-Ferraros, C. & Menendez, J. A. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9, 1057–64 (2010).
Buono, R. & Longo, V. D. Starvation, Stress Resistance, and Cancer. Trends Endocrinol. Metab. 29, 271–280 (2018).
Jiang, W., Zhu, Z. & Thompson, H. J. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res. 68, 5492–9 (2008).
Schulze, K., Nault, J. C. & Villanueva, A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J. Hepatol. 65, 1031–1042 (2016).
Li, L. & Wang, H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 379, 191–197 (2016).
Neumann, D., Woods, A., Carling, D., Wallimann, T. & Schlattner, U. Mammalian AMP-activated protein kinase: functional heterotrimeric complexes by co-expression of subunits in Escherichia coli. Protein Expr. Purif. 30, 230–237 (2003).
Woods, A. et al. Identification of phosphorylation sites in AMP activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site directed mutagenesis. J. Biol. Chem. 278, 28434–28442 (2003).
Ferretti, A. C., Mattaloni, S. M., Ochoa, J. E., Larocca, M. C. & Favre, C. Protein kinase A signals apoptotic activation in glucose-deprived hepatocytes: participation of reactive oxygen species. Apoptosis 17, 475–491 (2012).
Tonucci, F. M. et al. Centrosomal AKAP350 and CIP4 act in concert to define the polarized localization of the centrosome and Golgi in migratory cells. J. Cell Sci. 128, 3277–3289 (2015).
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275 (1951).
Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685 (1970).
This work was funded by the Argentinean Government with ANPCyT (PICT 2012 No 1362) and CONICET (PIP No 11220120100287CO) grants. Authors specially thank Dr. M. Ojeda (CONICET) for her technical assistance in cytometric analyses, Professor J. Bussi (University of Rosario) for his advice in English translation, and Dr. D. Neumann (Maastricht University) for his kind gift of AMPKα plasmids.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ferretti, A.C., Hidalgo, F., Tonucci, F.M. et al. Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration. Sci Rep 9, 2815 (2019). https://doi.org/10.1038/s41598-019-39556-w
Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts
Journal of Translational Medicine (2021)
AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism
High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells
Scientific Reports (2021)
Cilostazol Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma Cells by Activating AMPK
Biotechnology and Bioprocess Engineering (2021)
PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
Scientific Reports (2020)